ETFdb Logo
ETFdb Logo
  • ETF Database
  • Channels
    • Themes
      • Active ETF
      • Artificial Intelligence
      • Beyond Basic Beta
      • China Insights
      • Climate Insights
      • Core Strategies
      • Crypto
      • Direct Indexing
      • Disruptive Technology
      • Energy Infrastructure
      • ETF Building Blocks
      • ETF Investing
      • ETF Education
      • ETF Strategist
      • Financial Literacy
      • Fixed Income
      • Free Cash Flow
      • Innovative ETFs
      • Institutional Income Strategies
      • Leveraged & Inverse
      • Managed Futures
      • Market Insights
      • Modern Alpha
      • Multifactor
      • Responsible Investing
      • Retirement Income
      • Tax Efficient Income
    • Asset Class
      • Equity
        • U.S. Equity
        • Int'l Developed
        • Emerging Market Equities
      • Alternatives
        • Commodities
        • Gold/Silver/Critical Minerals
        • Currency
        • Volatility
      • Fixed Income
        • Investment Grade Corporates
        • US Treasuries & TIPS
        • High Yield Corporates
        • Int'l Fixed Income
    • ETF Ecosystem
    • ETFs in Canada
  • Tools
    • ETF Screener
    • ETF Country Exposure Tool
    • ETF Sector Tracker Tool
    • ETF Database Categories
    • Head-To-Head ETF Comparison Tool
    • ETF Stock Exposure Tool
    • ETF Issuer Fund Flows
    • Indexes
    • Mutual Fund To ETF Converter
  • Research
    • ETF Education
    • Equity Investing
    • Dividend ETFs
    • Leveraged ETFs
    • Inverse ETFs
    • Index Education
    • Index Insights
    • Top ETF Sectors
    • Top ETF Issuers
    • Top ETF Industries
  • Webcasts
  • Themes
    • AI ETFs
    • Blockchain ETFs
    • See all Thematic Investing ETF themes
    • ESG Investing
    • Marijuana ETFs
  • Multimedia
    • ETF 360 Video Series
    • ETF of the Week Podcast
    • ETF Prime Podcast
    • Video
  • Company
    • About VettaFi
    • Get VettaFi’ed
  • PRO
    • Pro Content
    • Pro Tools
    • Advanced
    • FAQ
    • Pricing
    • Free Sign Up
    • Login
  1. Beyond Basic Beta Channel
  2. Strong Vaccine Demand Boosting Pharma Sales
Beyond Basic Beta Channel
Share

Strong Vaccine Demand Boosting Pharma Sales

Tom LydonSep 02, 2021
2021-09-02

There are multiple coronavirus vaccines on the market, and with the likelihood of booster shots increasing by the day, the revenue outlook for healthcare exchange traded funds, including the VanEck Vectors Pharmaceutical ETF (PPH A-), is improving.

PPH tracks the MVIS US Listed Pharmaceutical 25 Index and is home to 25 stocks, several of which are purveyors of coronavirus vaccines. That includes Pfizer (NYSE:PFE), PPH’s third-largest holding.

“The US Food and Drug Administration’s (FDA) full approval of the Pfizer (A/Negative)-BioNTech vaccine for individuals at least 16 years of age this week should support demand as it may lower inoculation hesitancy,” says Fitch Ratings. “Full FDA approval may also help justify more private employer vaccine mandates. Some states, however, are blocking government-entity mandates.”

Dow component Johnson & Johnson (NYSE:JNJ), another leader in the fight against COVID-19, has yet to approach the FDA for full approval of its coronavirus vaccine. Johnson & Johnson is the sixth-largest PPH holding, commanding a weight of 5%, according to issuer data.

Unfortunately, the virus isn’t yet vanquished, and as is being seen with the Delta variant, the coronavirus mutates and creates new strains. How long that will continue remains to be seen, but between new variants and the fact that boosters are required, PPH components are gaining a new revenue stream.

“Drug makers will likely continue to reap financial benefits from the vaccine as long as the virus continues to circulate,” adds Fitch. “Vaccine efficacy is less than 12 months, based on scientific data reported by manufacturers, as there is potential for mutations that may or may not be more contagious than the original strain. A large portion of the world’s population is also still unvaccinated.”

Additionally, there’s ample runway for some PPH holdings to grow sales simply because global vaccination rates are low. Just a third of adults worldwide have received at least one jab, while only a quarter are fully vaccinated, according to Fitch. COVID-19 vaccines are having a material impact for some PPH constituents.

“Aggregate vaccine sales generated by Pfizer, Moderna, Johnson & Johnson and AstraZeneca, the four largest coronavirus vaccine manufacturers, during 1H21 totaled $18.6 billion, according to an Axios report. The report projects combined worldwide sales will reach $60 billion for the entire year, with Pfizer accounting for more than half,” said Fitch.

AstraZeneca (NYSE:AZN) is PPH’s second-largest holding at a weight of 5.72%.

VanEck Vectors Pharmaceutical ETF

For more news, information, and strategy, visit the Beyond Basic Beta Channel.


Content continues below advertisement

Loading Articles...
Our Sites
  • VettaFi
  • Advisor Perspectives
  • ETF Trends
Tools
  • ETF Screener
  • Mutual Fund to ETF Converter
  • Head-To-Head ETF Comparison
  • ETF Country Exposure Tool
  • ETF Stock Exposure Tool
  • ETF Database Pro
More Tools
  • Financial Advisor & RIA Center
Explore ETFs
  • ETF News
  • ETF Category Reports
  • Premium Articles
  • Alphabetical Listing of ETFs
  • Browse ETFs by ETF Database Category
  • Browse ETFs by Index
  • Browse ETFs by Issuer
  • Compare ETFs
Information
  • Contact Us
  • Terms of Use and Privacy Policy
  • © 2023 VettaFi LLC. All rights reserved.

Advertisement

Is Your Portfolio Positioned With Enough Global Exposure?

ETF Education Channel

How to Allocate Commodities in Portfolios

Tom LydonApr 26, 2022
2022-04-26

A long-running debate in asset allocation circles is how much of a portfolio an investor should...

Core Strategies Channel

Why ETFs Experience Limit Up/Down Protections

Karrie GordonMay 13, 2022
2022-05-13

In a digital age where information moves in milliseconds and millions of participants can transact...

}
X